搜索
Products
Bismuth Potassium Citrate Tablets
Product Description
Parameters
Scan the QR code to read on your phone
Retail price
0.0
元
Market price
0.0
元
Number of views:
1000
Product serial number
Category
Specialty Products
Quantity
-
+
Stock:
0
1
There is currently no information to display
相关产品
the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01
In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
Recombinant Human Choriogonadotropin alfa for Injection
Tocilizumab Injection
在线留言
不良报告
Description: